Final Common Pathway (Cardiomyopathy)
Definition
The "final common pathway" hypothesis states that hereditary cardiovascular diseases with similar phenotypes and genetic heterogeneity arise from abnormalities in genes encoding proteins of similar function or proteins participating in a common cascade. First described in 1998, it has proven predictive for gene and protein discovery across multiple cardiomyopathy subtypes.
Key Concepts
Application to Cardiomyopathies
- HCM: Final common pathway = sarcomere dysfunction (MYH7, MYBPC3, and other sarcomeric genes)
- LQTS/BrS/CPVT: Final common pathway = ion channel dysfunction
- Noonan syndrome: Ras signaling pathway
- ARVC: Final common pathway = desmosomal/intercalated disc dysfunction
- ALVC and biventricular ACM: Overlapping pathways — desmosome + sarcomere + ion channel pathways interact
(sources/acm-hrs-2019)
Intercalated Disc as the ACM Convergence Point
- The intercalated disc (ID) integrates three structures: desmosomes (IF attachment), adherens junctions (actin attachment), and gap junctions (electrical coupling), plus ion channels.
- These components are not independent; they form the "area composita" — a hybrid zone shared by desmosomal and adherens junction proteins.
- Dysfunction in any ID component (PKP2 loss → reduced Nav1.5/Cx43; desmoplakin loss → desmin uncoupling; N-cadherin loss → dissolution of entire ID structure) converges on the same endpoint: conduction slowing, fibrofatty replacement, and arrhythmia. (sources/acm-hrs-2019)
- This explains why genes outside the classical desmosome (CTNNA3 encoding αT-catenin, CDH2 encoding N-cadherin) also cause ARVC-like phenotypes.
Protein-Protein Interactions Bridging Pathways
- PKP2 (desmosomal) co-precipitates with Nav1.5 (ion channel) → primary desmosomal mutations secondarily impair sodium current
- β-catenin (adherens junction) is sequestered at the ID; PKP2 loss releases it → activates Wnt signaling → adipogenesis/fibrosis (the molecular basis of fibrofatty replacement in ARVC)
- ZASP/LDB3 (Z-disc) stabilizes Nav1.5 at T-tubular membrane via α-actinin-2 → cytoskeletal mutations impair ion channel function (sources/acm-hrs-2019)
Clinical Utility
- Knowledge of final common pathway proteins guides panel gene selection — genes encoding binding partners of known disease proteins are candidate ACM genes.
- Overlap between ACM and DCM pathways (cytoskeletal proteins: LMNA, DES, FLNC) explains phenotypic continuum and guides genotype-specific risk stratification.
- Novel therapeutic targets can be identified by mapping pathway nodes (e.g., Wnt/β-catenin for fibrofatty replacement).
Contradictions / Open Questions
- Evidence largely from PKP2 — extrapolation to other genes: The intercalated disc convergence model (PKP2 → reduced Nav1.5 + Cx43 → conduction slowing + arrhythmia) is best established for PKP2. Whether LMNA, FLNC, and DES (cytoskeletal genes) converge on the same disc pathology via the same mechanisms, or whether they represent truly independent pathways to arrhythmia, is unclear. The "final common pathway" label may overstate mechanistic unity across genetically diverse ACM. (sources/acm-hrs-2019)
- Pathway model does not explain all phenotype variability: The final common pathway hypothesis predicts that genes sharing the same pathway should produce similar phenotypes. In practice, PKP2 causes predominantly RV disease while LMNA causes predominantly conduction disease and LV dysfunction, and PLN causes calcium-handling dysfunction with LV involvement. The phenotypic divergence among "final common pathway" genes suggests that the convergence model is incomplete. (sources/acm-hrs-2019)
Connections
- Related to concepts/Arrhythmogenic-Cardiomyopathy
- Related to concepts/Desmosome
- Related to entities/ARVC
- Related to entities/ALVC
- Related to entities/PKP2
- Related to entities/SCN5A
- Related to concepts/Ion-Channel-Mutations